Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02168595 · ClinicalTrials.gov registry record · Phase 1
Placebo-controlled Single Dose Study to Evaluate Safety and Pharmacokinetics of GMI-1271 in Healthy Volunteers
A Phase 1 study, sponsored by GlycoMimetics Incorporated.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT02168595: Completed Phase 1 study, sponsored by GlycoMimetics Incorporated.
NCT02168595 is a Phase 1 study that has completed, run by GlycoMimetics Incorporated. The registered enrollment target is 28 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (53% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02168595, a Phase 1 study, has completed, sponsored by GlycoMimetics Incorporated.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate safety, tolerability and pharmacokinetics of single ascending IV doses of GMI-1271 in healthy adult subjects.
Primary Outcome
Treatment related adverse events as a measure of safety and tolerability of GMI-1271 (time frame: Day 1-15)
Interventions
- DRUG Placebo
- DRUG GMI-1271
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2014-06 |
| Est. Completion | 2015-04 |
| Phase | Phase 1 |
What the finished NCT02168595 record still lists
NCT02168595 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (53% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02168595 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02168595 about?
NCT02168595 is a clinical study titled "Placebo-controlled Single Dose Study to Evaluate Safety and Pharmacokinetics of GMI-1271 in Healthy Volunteers". The purpose of this study is to evaluate safety, tolerability and pharmacokinetics of single ascending IV doses of GMI-1271 in healthy adult subjects.
What is the current status of trial NCT02168595?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2014-06. Estimated completion is 2015-04.
What interventions are being tested in trial NCT02168595?
The interventions under investigation include: Placebo (DRUG), GMI-1271 (DRUG).
Who is sponsoring clinical trial NCT02168595?
This trial is sponsored by GlycoMimetics Incorporated, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02168595's enrollment target sits among peer trials
28 1447th of 2000 higher than 538 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia